Edgardo Santos, M.D., FACP, Florida Precision Oncology
Snehal Thakkar, M.D., Medical Affairs Director, Precision Oncology at Exact Sciences
Jean-Paul De La O, Ph.D., Sr. MSL, Precision Oncology at Exact Sciences
Two opportunities to attend live!
Wednesday May 19, 2021, 4-5pm PT
Monday May 24, 2021, 2-3pm PT
Drs. Edgardo Santos, Snehal Thakkar, and Jean-Paul De La O will discuss the growing importance of genomic profiling in light of recent guidelines and new targeted treatment options, and how the Oncotype MAP Pan-Cancer Tissue test can be used to help guide therapy selection decisions. They will also present real-world case studies that demonstrate how molecular testing has been used to enhance patient care.
- The growing need for NGS testing and genomic profiling in light of recent guidelines and new targeted treatment options
- How the new Oncotype MAP Pan-Cancer Tissue Test can be used to aid therapy selection for patients with advanced, metastatic, refractory, relapsed or recurrent cancer
- Real-world NSCLC case studies demonstrating how genomic profiling has been used to enhance patient care
IHC = immunohistochemistry
NCCN = National Comprehensive Cancer Network®
NGS = Next-generation sequencing
NSCLC = non-small cell lung cancer
NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer V.4.2021. © National Conmprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed May 6, 2021. To view the most recent and complete version of the guideline, go online to www.nccn.org/guidelines/ .
1. Malone et al. Genome Med. 2020.
Comparative turnaround time data on file.